Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.
2.

Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.

Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):205-9. Review.

PMID:
12880983
3.

Disialoganglioside directed immunotherapy of neuroblastoma.

Modak S, Cheung NK.

Cancer Invest. 2007 Feb;25(1):67-77. Review.

PMID:
17364560
4.

Immunotherapy with GD2 specific monoclonal antibodies.

Cheung NK, Medof ME, Munn D.

Prog Clin Biol Res. 1988;271:619-32. Review. No abstract available.

PMID:
3043454
5.

Immunogenicity of human neuroblastoma.

Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V.

Ann N Y Acad Sci. 2004 Dec;1028:69-80. Review.

PMID:
15650233
6.

Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.

Cheung NK, Munn D, Kushner BH, Usmani N, Yeh SD.

Int J Rad Appl Instrum B. 1989;16(2):111-20. Review. No abstract available.

PMID:
2497088
7.

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.

Ahmed M, Cheung NK.

FEBS Lett. 2014 Jan 21;588(2):288-97. doi: 10.1016/j.febslet.2013.11.030. Epub 2013 Dec 1. Review.

8.

Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Perez Horta Z, Goldberg JL, Sondel PM.

Immunotherapy. 2016 Sep;8(9):1097-117. doi: 10.2217/imt-2016-0021. Review. Erratum in: Immunotherapy. 2016 Nov;8(11):1349.

9.

Treatment of high-risk neuroblastoma with anti-GD2 antibodies.

Castel V, Segura V, CaƱete A.

Clin Transl Oncol. 2010 Dec;12(12):788-93. doi: 10.1007/s12094-010-0600-y. Review.

PMID:
21156409
10.

Immunology and immunotherapy of neuroblastoma.

Seeger RC.

Semin Cancer Biol. 2011 Oct;21(4):229-37. doi: 10.1016/j.semcancer.2011.09.012. Epub 2011 Sep 28. Review.

11.

GD2-targeted immunotherapy and radioimmunotherapy.

Dobrenkov K, Cheung NK.

Semin Oncol. 2014 Oct;41(5):589-612. doi: 10.1053/j.seminoncol.2014.07.003. Epub 2014 Jul 21. Review.

12.

Advances in chimeric antigen receptor immunotherapy for neuroblastoma.

Heczey A, Louis CU.

Discov Med. 2013 Dec;16(90):287-94. Review.

13.

Immune therapies for neuroblastoma.

Navid F, Armstrong M, Barfield RC.

Cancer Biol Ther. 2009 May;8(10):874-82. Epub 2009 May 9. Review.

14.

Anti-GD2 antibody therapy for GD2-expressing tumors.

Navid F, Santana VM, Barfield RC.

Curr Cancer Drug Targets. 2010 Mar;10(2):200-9. Review.

15.

Potential of genetically engineered monoclonal antibodies for cancer immunotherapy.

Reisfeld RA.

Pigment Cell Res. 1992;Suppl 2:109-12. Review. No abstract available.

PMID:
1409412
16.

Dinutuximab: first global approval.

Dhillon S.

Drugs. 2015 May;75(8):923-7. doi: 10.1007/s40265-015-0399-5. Review. Erratum in: Drugs. 2015 Oct;75(15):1831. Drugs. 2015 Oct;75(15):1831.

PMID:
25940913
17.

Monoclonal antibodies and neuroblastoma.

Miraldi F.

Semin Nucl Med. 1989 Oct;19(4):282-94. Review.

PMID:
2678480
18.

Dinutuximab for maintenance therapy in pediatric neuroblastoma.

McGinty L, Kolesar J.

Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567. doi: 10.2146/ajhp160228. Review.

PMID:
28389455
19.

Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.

Berois N, Osinaga E.

Front Oncol. 2014 May 23;4:114. doi: 10.3389/fonc.2014.00114. eCollection 2014. Review.

Supplemental Content

Support Center